BUILDING A NEW KIND OF HEALTH CARE COMPANY —
The Transformation Unfolds
Schering-Plough 2005 Company Overview
Schering-Plough is a global pharmaceutical company with leading
prescription, consumer and animal health products. Today, the Company
is focused on delivering the Turnaround phase of its five-step Action
Agenda, the blueprint for a fundamental transformation that began in 2003.
Our goal is to provide a steady flow of innovative, science-based medicines
and services, and to earn the trust of the physicians, patients and
other customers we serve. By doing this well, we seek to build long-term,
sustainable growth. In everything we do, we remain committed to
business integrity, quality and compliance.
Cover Story: “Knowing that people are depending on encountering scientific challenges,
you makes me realize how important situations where you know the answer
the work we do here is. As an analytical is out there and it’s just a matter of
Kristan Amicone is a scientist in Analytical
Development, Pharmaceutical Sciences, chemist, my job is to make sure that finding it. Through cross-functional team-
for Schering-Plough Research Institute
only high-quality, effective medications work and collaboration, we find those
in Kenilworth, N.J. She works as an ana-
lytical chemist primarily on pharmaceuti- get to the patients in our clinical trials answers, and in the process help make
cals in late-stage development.
and in the health care systems. We do sure Schering-Plough continues providing
this by developing laboratory experi- a reliable supply of high-quality medi-
ments to test the purity, potency and cines that do good things for patients.”
stability of our medicines. We’re always - Kristan Amicone
Fred Hassan, chairman and chief executive officer, Schering-Plough Corporation.
A Message from “It all begins with the people.” the people of Schering-Plough are
steadily building an exciting new
the CEO This mindset has been driving a remark- enterprise. Step by step, we are suc-
able and continuing transformation of ceeding – and growing.
our organization. Today, I look with a
lot of pride at what has been achieved The roadmap for our transformation has
by putting such faith in our people. been a six- to eight-year Action
Agenda that began with the Stabilize
Out of a company that was under and Repair phases. Even as important
severe stress three years ago, dimensions of that work continue,
we are now deeply engaged in driving cal education and patient-access also meeting with our customers
our Turnaround phase. We are moving programs. We see our role as a and with other stakeholders. What I
from survive mode into thrive mode. champion for doctors and patients. see and hear is that our teams are
We are investing for the long term – energized. They are passionate.
in better processes, in our supply chain, Our aim is to become very good in They are getting in tune with each
in research and development, and in every dimension of our work, to keep other and with our stakeholders.
other areas, around the world. learning, improving and reinventing They are taking the time to listen
ourselves. Our people know that to others and to learn. They are
This long-term commitment is so superb medical science must be at striving to execute with excellence.
important because bringing new the heart of this.
medicines from the lab to patients is When we began this transformational
a 10- to 15-year process. For example, We also feel a special responsibility. journey almost three years ago, we
we are investing heavily in creating We understand that our work directly said that our vision was to earn trust –
a new treatment for hepatitis C. affects the health and happiness of with each other, in our Company, and
This compound could change the way patients. We know that the potential with our stakeholders. We know that
doctors treat tens of thousands new medicines in our pipeline are trust gets earned by behavior and per-
of patients suffering from this terrible precious discoveries. They could save formance. Step by step, we believe
disease. It is one of a number of someone from cancer, prevent heart we are making progress.
promising new therapies that disease, or bring new treatments to
we are advancing from our labs people living with HIV/AIDS. As we look ahead, we see a bright
toward patients. and fresh dawn breaking for Schering-
This sense of special purpose is part Plough. We have a lot of challenges
Everywhere we look today, the health of what makes me feel good about ahead, but I have confidence about
care environment is changing at this Company and what we are doing. our growing strength to overcome
high speed. This can be unsettling, I am also moved by the attitude and them. Above all, it is rewarding to
even frightening – especially for performance of our people. know that we are succeeding because
more vulnerable populations. As we we are doing good things for health.
drive the continuing transformation Our people have shown a special
of Schering-Plough, we are striving to courage in confronting the difficult Yes, it all begins with the people.
put the patient at the center of how challenges we have faced as we build
we think and what we do. a new Schering-Plough. They are learn- Sincerely,
ing and growing in a unique school of
We are working hard to create value transformational change.
through superior R&D and manufac-
turing, and then transfer the value I spend a lot of my time visiting our Fred Hassan
through empathetic and useful medi- operations around the world and Chairman and Chief Executive Officer
Fred Hassan and
Leon G. Smith,
Fred Hassan, Schering-Plough chairman and CEO, and Leon G. Smith, M.D., M.A.C.P.,
chairman of Medicine at Saint Michael’s Medical Center, Newark, N.J., and executive vice
president, Health Care Policy, for Catholic Health & Human Services, exchanged ideas
(below) on current health care issues and pharmaceutical research challenges. Dr. Smith
is a practicing physician and globally recognized infectious disease expert.
Hepatitis C is such an under-treated new treatments, not only for hepatitis C Some people have the expectation that
and misunderstood disease. What can and HIV/AIDS, but for other serious everything can be solved, and that they
be done to improve this situation? infections. Avian flu appears to show us do not have responsibilities. The reality
also – again – the challenge posed by is that we all need to take responsibility
Hepatitis C causes enormous organisms that mutate and can resist for our own health, for health mainte-
damage to societies around the world. established treatments. The bacterial nance and disease prevention. Things like
It is the number one cause of liver resistance problem is huge and growing. eating right, getting exercise, not smok-
transplants in this country. In some ing, getting vaccinated.
places it is a worse problem even than This is an area in which research-
HIV/AIDS, and it is also very commonly based pharmaceutical and biopharma Speaking of health literacy and
a co-infection with HIV. companies could have been doing much awareness, what about advertisements
more over the past decade or so. for prescription drugs?
The key needs right now are to get better Now attention is being re-focused on this
screening for HCV so people can get area. It is an important example of where I actually believe even more
treatment, and we need to have better the key is to keep thinking outside of communication with consumers,
health literacy and behavior so people the box, not accepting common wisdom. including more advertising, would be
do not get infected in the first place. appropriate. It’s all in how you do it.
How it is executed is key. I personally
Choices about prescribing and
This disease still carries a stigma, feel health education advertising about
taking medicines depend on striking
somewhat like HIV/AIDS. We must disease states would be compelling.
a balance between effectiveness and
break down that stigma. This will take safety. Where are we today, post the
courage, including political courage. Advertising and other communi-
Vioxx withdrawal? HASSAN:
Also, we need better treatments. While cations with consumers are something
treatment has improved, there is still The pendulum has clearly swung relatively new when it comes to prescrip-
a huge, unmet need. too far. We are seeing a preoccupation tion drugs. Everyone is learning. As a
with safety that could begin to harm the result, I think you will see different kinds
Not long ago many people said that flow of new treatments that patients of communications in the next few
there was not a big need for new need. If we expect total safety from a years – more appropriate, more tailored
treatments for infectious diseases. medicine, we will have no new medicines. to the special situations of health care.
Now we hear about new, resistant Even aspirin has side effects. This calls
strains of bacteria and, of course, the for a much higher level of health and
avian flu threat. What’s going on? science literacy in our societies.
Then we can begin to get the right,
It was a big mistake to be balanced approach.
complacent – although I have to say
I have never felt complacent about Another way of looking at this
infectious disease! Clearly we need is that expectations are unrealistic.
“It All Begins With
The people of Schering-Plough are making our
transformation happen. With passion, courage and tenacity,
they are building a new kind of health care company.
In the pages that follow, some of our people introduce
themselves and what they do.
Jerry Shipps, Ph.D., is director of chemical research for Schering-Plough Research Institute in Cambridge, Mass. He also is the scientific co-founder
of NeoGenesis Pharmaceuticals, Inc., from which Schering-Plough acquired assets in 2005. His team in Lead Discovery focuses on identifying drug
development candidates in cancer, inflammation and infection.
“We work at the forefront “In our labs, we apply proprietary screening this process, and to work for a major
and chemistry technologies to identify pharmaceutical company that can take a
of science in drug novel, active compounds. Someday these compound from early discovery to
discovery, looking for new compounds or variations may become the global health care marketplace.”
medicines to treat cancer, inflammation
compounds to affect
or infection. The idea that my work could
the pathways of disease.” in the future help improve someone’s
health or save a life is compelling. I find
it exciting and energizing to be part of - Jerry Shipps, Ph.D.
Bo Kwok is a district trainer and professional sales representative for respiratory products. Her territory is Manhattan South in New York City.
“It’s rewarding to know “The patient is really the focus of what I goal – making the best treatment
do. As a sales representative, I’m on choices for their patients. I feel great
that the scientific the frontlines every day, speaking with when I hear about success stories
information I provide can health care professionals who directly and how better treatment has helped
counsel and treat patients. I work hard to improve the health of a patient.”
help doctors make better
build relationships with my customers –
treatment decisions for and to earn their trust. I find that this
their patients.” happens when I am providing new infor-
mation that helps them achieve their - Bo Kwok
Maria Teresa Rico is general manager, Greece, based in Athens. She is responsible for Schering-Plough’s business operations in Greece and Cyprus.
“What makes me feel “Our goal is to deliver on our commitments by being aligned in how we work, we are
and to earn the trust of our stakeholders. adding value and serving our patients
great is coaching my One of the key initiatives in my country and doctors better.”
people and seeing operation has been to bring alive our
Company’s commitment to a collaborative,
them make a difference.”
shared-accountability way of working
with colleagues. This is resulting in a
better, more efficient and trusted organi-
zation. In Greece, we are seeing that, - Maria Teresa Rico
Stephen Morales is senior product manager, Global Cholesterol Marketing, in Kenilworth, N.J. His responsibilities include the marketing of Vytorin
and Zetia, cholesterol-lowering medicines managed through a joint venture with Merck & Co., Inc.
“Science is at the center “Communicating science and information rewarding working with researchers
is an important part of my job. We work to communicate the science behind
of our cholesterol-lowering to provide doctors with the tools they Vytorin and Zetia. Sharing scientific
franchise, and it adds a need to help their patients understand innovation and education ultimately
the value of lowering their cholesterol, benefits patients, helping them live
powerful message for
of getting to goal. High cholesterol is one healthier lives.”
our products.” of the major risk factors for heart disease,
a leading killer of women and men
around the world. This is why I find it so - Stephen Morales
Beth Anne Lange, Ph.D., is senior director of Sun Care R&D and New Technologies for Consumer Health Care in Memphis, Tenn. Her team in
Sun Care R&D develops innovative sunscreen products. In New Technologies R&D, her team identifies novel technology solutions for sun care and
foot care products and over-the-counter medicines.
“It’s fascinating to work “Skin cancer is the most prevalent of all new benefits. Coppertone Continuous
types of cancers, yet it is largely prevent- spray Sunscreen is an example of
on creating technology able. We need to find ways to make it how we joined a known packaging
solutions that can deliver easier and more pleasant for consumers system and sunscreen formulation
to protect themselves against the to create a significantly improved
damaging effects of the sun. In Sun Care consumer experience.”
benefits for consumers.” R&D and New Technologies, we’re dedi-
cated to identifying technology solutions
to create innovative products that bring - Beth Anne Lange, Ph.D.
Colin Walters is a principal scientist, Pharmaceutical Development, in Kenilworth, N.J. He provides technical leadership in developing manufacturing
processes for oral dosage forms of Schering-Plough products.
“Turning a compound “I’m part of a team working directly in the process – through scale-up and technology
product flow pathway from the discovery transfer to the commercial manufacturing
into a medicine that laboratory to the patient. We develop site -- we work to ensure that our
can be manufactured manufacturing processes for oral dosage compounds consistently meet high quality
products for Schering-Plough, providing standards. I learn something new every
scientific expertise and technical support day in this job, as the science and tech-
challenging – and during the small-scale manufacture nology continue to evolve.”
rewarding.” of compounds used in clinical trials.
Throughout the development - Colin Walters
Every medicine we create begins as their patients, our scientists learned that
an idea in the mind of one of our people. the most disturbing aspect of the disease
Often the spark comes from witnessing was not the tremors but rather the akine-
firsthand a patient’s medical need. sia, or sudden inability to move. So our
At Schering-Plough, an important part scientists began focusing on this aspect
of my job is to create an environment back in the labs, and today this thinking
that allows those ideas to develop into is driving our continuing research into
successful drugs – by putting science movement disorders.
at the center of a highly collaborative
way of working. Similarly, meeting with cancer patients
or confronting the tragedy of Alzheimer’s
disease drives our discovery and clinical
“Meeting with cancer scientists to work even harder to discover
a drug that has the “legs” to make it all
patients or confronting the
the way through initial development and
tragedy of Alzheimer’s clinical testing to the patient.
disease drives our discovery
Another factor in deciding what to pursue
and clinical scientists
is determining what is mechanistically
to work even harder.” possible. We focus much of our research
efforts on molecular targets that have the
potential to become sources of drugs for
multiple therapeutic areas. At Schering-
Our primary driver in deciding what Plough, both small molecule and biologics
treatments to pursue is medical need. efforts are integrated into a single discov-
Input for that comes from a variety of ery organization, positioning us to adopt
sources. Communication with physicians the best approach for each therapeutic tar-
and with patients themselves is an get. Our Company’s size, the proximity of
important source of insight, as are new our researchers to one another, and their
scientific findings from labs around collaborative behaviors produce a synergy
the world. across these approaches that makes the
science move faster. We further strength-
A few years ago some of our scientists ened our small molecule and biologics
in Milan, Italy, were studying Parkinson’s capabilities in 2005 with the consolidation
disease and wanted to learn more about of our California labs to form Schering-
what patients really need. By sitting Plough Biopharma and the opening of our
down and talking with neurologists and new research site in Cambridge, Mass.
Innovation also results from the science
we apply to existing projects and treat-
ments. For example, interferon alfa-2b
started out as a treatment for hairy cell
leukemia, a rare cancer. Through the
continued application of clinical science,
we discovered new uses, more effective
drug combinations and more convenient
Catherine D. Strader, Ph.D., is executive vice president for Discovery Research at Schering-Plough
formulations. PeG-Intron/Rebetol com- Research Institute in Kenilworth, N.J. She is responsible for Schering-Plough’s global drug
discovery operations, including biology, genomics, medicinal and structural chemistry research,
bination therapy is now a standard of
conducted through both internal programs and external collaborations.
care for hepatitis C. This kind of research
expands the utility of our medicines,
with the result that more patients benefit.
“Patients are waiting for cardiovascular and neurological diseases.
For patients, new drug delivery systems As we set our research goals, we believe
these new treatments.
and formulations can be important it is very important that we continue
This is what gives our work
medical innovations. If a new formulation to go after new frontiers. This is where
makes it possible for a patient to take the risk of failure is very high, but where,
one pill a day instead of three, that’s if we succeed, we can really change
a change that can ensure more consis- the paradigm for treating disease.
tent dosing and yield a better medical Patients are waiting for these new treat-
outcome. The pharmaceutical science strategy. Conversely, knowledge gained ments. This is what gives our work
behind these types of innovations is during the development process can such urgency.
a real strength within Schering-Plough. have a tremendous impact on the next
compound in our discovery pipeline.
One of the hallmarks of Schering- This same collaborative mindset makes
Plough’s science is that we focus on us attractive as a partner to smaller
getting the job done, not on artificial biotech companies and other outside
boundaries. Discovery and development organizations.
scientists collaborate with physicians
outside the Company and with Schering-Plough invested $1.9 billion in
commercial colleagues to bring a drug research and development in 2005, and
forward in our pipeline. Wonderful in- we expect to spend more in future years.
sights come from these collaborations. These investments have built a strong
early development pipeline, with potential
The science behind the discovery of treatments for oncology, inflammation,
a compound drives the development infectious and respiratory diseases, and - Catherine D. Strader, Ph.D.
“Our business is based Our Customer Focus Our business is based on science.
We seek to discover new molecules
on science. We seek to
that can prevent, modify or block
At Schering-Plough, we organize and
discover new molecules the progression of disease. When we
develop our product lines around our
that can prevent, succeed, patients benefit.
customers. For primary care physicians,
we bring together medicines that will
modify or block the In addition to prescription pharmaceu-
be most useful to them and appropriate
progression of disease. ticals, we also develop and market
for the patients they treat. In specialty
consumer and animal health products.
When we succeed, care, we group our products according
Our over-the-counter business enables
to the needs of health professionals
patients benefit.” us to extend the life cycle of certain
treating specialized therapy areas, such as
products when their exclusivity as a
oncology and infectious disease, as well
prescription medicine expires.
as hospital-based treatment centers.
* Managed through a joint venture with Merck & Co., Inc.
* Sold by Schering-Plough in U.S. only
* Sold by Schering-Plough outside U.S. only
Consumer Health Care
(flunixin meglumine) (florfenicol)
betamethasone valerate USP,
See inside back cover for INFORMATION ON LICENSED PRODUCTS
Our animal health business also allows nonsedating antihistamines is now tumors; Caelyx, marketed outside of
Schering-Plough to take discoveries available in six formulations to help pa- the U.S. as a treatment for advanced
made in human pharmaceuticals and tients address their allergy symptoms. ovarian cancer, metastatic breast
find new applications in treating cancer and AIDS-related Kaposi’s
animal populations. Our U.S. primary care treatments sarcoma; and Intron A for malignant
also include the antibiotics Avelox and melanoma and other cancers.
Cipro and the erectile dysfunction
Cholesterol Franchise medicine Levitra (co-promoted with In cardiovascular care, we assumed
GlaxoSmithKline), under a strategic exclusive U.S. marketing rights in 2005
Schering-Plough has rapidly become a alliance with Bayer. to InteGrilin, a GP IIb-IIIa inhibitor used
global cardiovascular leader, building on primarily in hospitals to treat heart
the strength of its cholesterol franchise. patients with acute coronary syndrome,
Our cholesterol-lowering medicines are under a restructured agreement with
Vytorin and Zetia, managed through Millennium Pharmaceuticals, Inc.
a joint venture with Merck & Co., Inc. In hepatitis C, we are a global leader
in the discovery and development
Consumer Health Care
Cardiovascular disease is a leading killer of new therapies to treat this serious
around the world, with high cholesterol disease, which afflicts more than
being a major risk factor. Zetia and Vytorin 10 million people in developed world Our consumer offerings include over-
offer physicians valuable medicines markets. The Company offers the the-counter (OTC), sun care and
to address this serious health challenge. combination therapy of PEG-Intron, foot care products, primarily in North
Discovered by Schering-Plough a once-weekly alpha interferon, America. Our OTC brands include
researchers, Zetia is the first agent to with the antiviral agent Rebetol. Claritin, a leading non-drowsy allergy
selectively inhibit the absorption of medication, as well as other well-
cholesterol in the intestine. Vytorin The newest addition to our anti- established brands including Afrin
combines both Zetia and Merck’s Zocor infective portfolio is Noxafil, an oral and Coricidin.
(simvastatin) statin product. Vytorin treatment for serious invasive fungal
is the first and only once-daily medication infections. Noxafil was approved in With the well-known Coppertone brand,
able to inhibit both the absorption the European Union in October 2005. Schering-Plough is the leader in the
and production of cholesterol. A U.S. application was granted priority U.S. sun care market. Our foot care
review in February 2006. franchise also leads the North American
foot care market, anchored by the
Primary Care In the area of anti-inflammatory Dr. scholl’s brand.
agents, Remicade is a leading medicine
Schering-Plough has long been a leader in a class known as anti-tumor
in the U.S. respiratory market. For the necrosis factor alpha (TNF-alpha)
treatment of asthma, we broadened therapies. This monoclonal antibody
our U.S. product offerings in 2005 with has been shown to offer significant For the past 50 years, Schering-Plough’s
Asmanex Twisthaler, an orally inhaled benefits for patients with such global animal health business has
corticosteroid. The product is also avail- debilitating diseases as rheumatoid played an important role in extending
able in a number of international countries. arthritis, ankylosing spondylitis, the life-cycle of our prescription
We continue to make available in psoriatic arthritis, Crohn’s disease, medicines and the value of our R&D
the U.S. Foradil Aerolizer, a long-acting ulcerative colitis and psoriasis. investment. Today, these products
beta2 agonist, for asthma and chronic We make this therapy available in include pharmaceuticals, vaccines and
obstructive pulmonary disease. certain countries outside the U.S. parasiticides, having a presence in five
entry markets: ruminant, swine, live-
For treating allergies, Nasonex, a nasally Oncology is a treatment area where stock, poultry, companion animal and
inhaled corticosteroid, became the Schering-Plough intends to grow aquaculture. In addition, our HomeaGain
fastest-growing U.S. brand in its category its presence. We offer Temodar, pet recovery service has reunited
in 2005. The Clarinex family of a treatment for certain types of brain thousands of pets and owners.
Schering-Plough is a network of business, research and manufacturing operations reaching
around the world. We strive to work as a global team to ensure a steady supply of medicines to
our physicians, patients and other customers. We have a presence in more than 120 countries.
Below are listed the Company’s principal locations around the world.
GERMANY Burgwedel / Friesoythe / JORDAN Amman
CANADA Pointe-Claire Munich KAZAKHSTAN Almaty
UNITED STATES: GREECE Alimos LEBANON Beirut
California Palo Alto HUNGARY Budapest MALAYSIA Selangor
Delaware Millsboro IRELAND Bray / County Cork / Rathdrum NEW ZEALAND Upper Hutt
Florida Miami Lakes ITALY Comazzo / Lodi / Milan / Segrate PAKISTAN Islamabad
Georgia Atlanta / Suwanee PHILIPPINES Manila
Illinois Rolling Meadows LITHUANIA Vilnius SAUDI ARABIA Riyadh
Indiana Terre Haute NETHERLANDS Utrecht SINGAPORE
Kansas Williamsburg NORWAY Elksmarka SOUTH AFRICA Gauteng
Louisiana Baton Rouge POLAND Warszawa SOUTH KOREA Seoul
Maryland Rockville PORTUGAL Agualva-Cacem TAIWAN Taipei
Massachusetts Cambridge ROMANIA Bucharest THAILAND Bangkok
Nebraska Elkhorn / Omaha RUSSIA Moscow TURKEY Istanbul
Nevada Reno / Sparks SERBIA Belgrade
New Jersey Berkeley Heights / SLOVAK REPUBLIC Bratislava
Branchburg / Cranford / Kenilworth / SLOVENIA Ljublijana LATIN AMERICA
Lafayette / Madison / Springfield / SPAIN Madrid / San Agustin ARGENTINA Buenos Aires
Summit / Union SWEDEN Stockholm BRAZIL Cotia / Sao Paulo
Puerto Rico Las Piedras / Manati / SWITZERLAND Lucerne / Schachen / CHILE Santiago
Toa Baja Werthenstein COLOMBIA Bogota
Tennessee Cleveland / Memphis UKRAINE Kiev ECUADOR Quito
Washington, D.C. UNITED KINGDOM Hertfordshire / MEXICO Mexico City / Beisa
Suffolk / Middlesex PANAMA REPUBLIC Colon / Panama City
AUSTRIA Traiskirchen VENEZUELA Caracas
ASIA / AFRICA / AUSTRALIA
BELGIUM Brussels / Heist-Op-Den-Berg AUSTRALIA Sydney
BULGARIA Sofia CHINA Shanghai
CROATIA Zagreb EGYPT Cairo
CZECH REPUBLIC Prague GEORGIA Tbilisi
DENMARK Farum HONG KONG
ESTONIA Tallinn INDIA Mumbai
FINLAND Espoo INDONESIA Jakarta / Jawa Timur
FRANCE Herouvill-St-Clair / ISRAEL Petah Tikva
Levallois-Perret / Segre JAPAN Osaka / Shiga / Tokyo
Executive Offices: Corporate Web Site: INFORMATION ON LICENSED PRODUCTS
Schering-Plough has exclusive rights in the U.S.
The Company’s corporate headquarters The Company’s Web site address is and Puerto Rico under a 2004 strategic agreement
with Bayer to market, sell and distribute Bayer’s
is located at: http://www.schering-plough.com.
Avelox (moxifloxacin HCl) and Cipro (ciprofloxacin
2000 Galloping Hill Road, Schering-Plough’s Web site offers links HCl) antibiotics and to undertake Bayer’s U.S.
Kenilworth, N.J. 07033-0530 to other Web sites providing information commercialization activities for the erectile
dysfunction medicine Levitra (vardenafil HCl)
Telephone: (908) 298-4000 on Company products and treatment
under Bayer’s co-promotion agreement with
categories as well as patient assistance GlaxoSmithKline PLC.
and support programs. Information
Caelyx (pegylated liposomal doxorubicin HCI) is
of interest to shareholders is available
licensed for marketing outside the U.S., except in
in the Investor Relations section of Japan and Israel, from ALZA Corporation. Caelyx
the Web site, including news releases, is marketed as Doxil® in the U.S. by Tibotec Thera-
peutics, Division of Ortho Biotech Products, L.P.
investor frequently asked questions,
Securities and Exchange Commission Schering-Plough has exclusive U.S. marketing
rights to Foradil Aerolizer (formoterol fumarate
filings, corporate governance guidelines
inhalation powder) under a 2002 agreement
and the charters of Committees of with Novartis Pharmaceuticals Corporation.
the Board of Directors.
Through a licensing agreement with Millennium
Pharmaceuticals, Inc., Schering-Plough markets
Integrilin (eptifibatide) Injection, a GP IIb/IIIa
Investor Inquiries: inhibitor, in the U.S. and certain countries outside
Information for investors can be found in the U.S.
the Investor Relations section of the Web
Peg-intron (peginterferon alfa-2b) uses propri-
site, or investors can call the Investor etary pegylation technology licensed from Enzon
Pharmaceuticals, Inc. From Valeant Pharmaceu-
Relations Department at (908) 298-7436.
ticals International, Schering-Plough has rights
to market oral ribavirin for hepatitis C in all major
Schering-Plough has marketing rights to
Information about possible career
RemiCade (infliximab) in all global markets except
opportunities at Schering-Plough can the U.S., China, Japan and parts of the Far
be found in the Careers section of East through an agreement with Centocor,
a Johnson & Johnson subsidiary.
the Company’s Web site,
http://www.schering-plough.com. Temodar (temozolomide) (marketed as Temodal in
certain countries) is licensed for worldwide
marketing from Cancer Research Technology Ltd.
New York Stock Exchange
(Ticker Symbol: SGP)
Building A New Kind Of Health Care Company —
The Transformation Unfolds
2000 Galloping Hill Road
Kenilworth, New Jersey 07033-0530